Montelukast and Telmisartan as Inhibitors of SARS-CoV-2 Omicron Variant.

ABSTRACT: Earlier studies with montelukast (M) and telmisartan (T) have revealed their potential antiviral properties against SARS-CoV-2 wild-type (WT) but have not assessed their efficacy against emerging Variants of Concern (VOCs) such as Omicron. Our research fills this gap by investigating these drugs' impact on VOCs, a topic that current scientific literature has largely overlooked. We employed computational methodologies, including molecular mechanics and machine learning tools, to identify drugs that could potentially disrupt the SARS-CoV-2 spike RBD-ACE2 protein interaction. This led to the identification of two FDA-approved small molecule drugs, M and T, conventionally used for treating asthma and hypertension, respectively. Our study presents an additional potential use for these drugs as

SUBMITTER: Mulgaonkar N 

PROVIDER: S-EPMC10385313 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature